文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

5倍乘数模型与3层模型:腹部肿瘤术后出院阿片处方的务实随机临床试验

5x-Multiplier Versus 3-Tier Model: A Pragmatic Randomized Clinical Trial for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery.
PubMed 文献 · Ann Surg · 2026-06-22

该单中心务实II期随机试验比较5倍乘数算法与封顶3层模型在腹部肿瘤切除术后出院阿片处方中的效果。5倍乘数组出院阿片剂量中位数25 mg OME显著低于3层模型组75 mg,但14天消耗量、补药率及满意度无差异。5倍乘数算法可减少出院阿片处方量而不增加消耗或降低满意度。

要点

  • 5倍乘数算法较3层模型显著降低出院阿片处方量(25 mg vs 75 mg OME)。
  • 两组14天阿片消耗量、补药率及满意度无显著差异。
  • 5倍乘数组44%患者出院时未使用阿片,3层模型组仅1%。

核心结论

  • 在腹部肿瘤手术后,5倍乘数算法相比3层模型减少了出院阿片处方量,且14天消耗量、补药率和满意度相似。

研究设计与样本

  • 务实单中心II期随机临床试验,纳入150例成人开腹腹部肿瘤切除术患者,随机分为5倍乘数组(73例)和3层模型组(77例)。

主要发现

  • 出院阿片剂量中位数5倍乘数组25 mg OME,3层模型组75 mg(P<0.001)。
  • 出院后14天阿片消耗中位数5倍乘数组0 mg,3层模型组10 mg(P=0.496)。
  • 补药率5倍乘数组24%,3层模型组18%(P=0.426)。
  • 两组患者满意度和症状清单评分无差异。

关键数值与推荐

  • 5倍乘数算法:最后24小时口服吗啡当量乘以5;3层模型:根据最后24小时OME 0、1-29、≥30 mg分别给予5、15、30片。

临床怎么用

  • 对于腹部肿瘤手术后出院患者,可采用5倍乘数算法以减少阿片处方量,而不增加14天消耗或补药需求。

局限性

  • 单中心研究可能限制外推性;样本量150例,为II期试验;未报告长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standardized prescribing models can reduce discharge opioid prescriptions and excess pill volumes, mitigating potential opioid dependence and diversion after abdominal operations. This study's objective was to determine which of 2 validated discharge prescribing models resulted in fewer opioids prescribed and consumed after major abdominal surgery. METHODS: This was a pragmatic single-center, phase II randomized clinical trial comparing 2 discharge opioid prescribing models: linear 5x-multiplier algorithm [last 24 h oral morphine equivalents (OME) times 5] versus capped 3-tier model (5/15/30 pills depending on 0/1-29/≥30 mg OME in last 24 h). Adults undergoing open abdominal cancer resections by 25 surgeons (5 specialties) were included. A nonopioid analgesic bundle was used perioperatively and at discharge. Coprimary endpoints were discharge opioid volume and 14-day post-discharge consumption. Secondary endpoints included patient satisfaction and symptom inventory. The power (80%) calculation was performed using the 2-sample t -test to detect a mean difference in OME with 0.05 significance (0.025 per co-primary outcomes). RESULTS: From April to December 2024, 150 patients (52% female; median age 63) were randomized: 73 to 5x-multiplier; 77 to 3-tier model. Operations included hepatectomy (32%), pancreatectomy (29%), nephrectomy (13%), thoracoabdominal sarcoma resection (15%), and ovarian cytoreduction (11%). Median discharge OME was 25 mg (5x-multiplier) versus 75 mg (3-tier, P <0.001), with 44% of 5x-multiplier patients discharged opioid-free (1% in 3-tier). Median post-discharge 14-day opioid consumption was 0 mg (5x-multiplier) versus 10 mg (3-tier, P =0.496). Refill rates were 24% (5x-multiplier) versus 18% (3-tier, P =0.426), consistent with historical rates, with no differences in satisfaction or symptom inventory scores. CONCLUSION: The 5x-multiplier algorithm resulted in fewer prescribed discharge opioids with similar 14-day consumption, refill rates, and satisfaction, compared with a 3-tier model after intra-abdominal cancer surgery.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Fields BC, Newhook TE, Lillemoe HA, et al. 5x-Multiplier Versus 3-Tier Model: A Pragmatic Randomized Clinical Trial for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery. Ann Surg. 2026. PMID: 42322127. doi:10.1097/SLA.0000000000007115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。